Literature DB >> 28271418

Blood Pressure and the Renal Actions of AT2 Receptors.

Robert M Carey1.   

Abstract

Angiotensin type-2 receptors (AT2Rs) in the renal proximal tubule inhibit sodium (Na+) reabsorption by inducing renal cyclic GMP formation and internalizing and inhibiting major Na+ transporters Na+-H+ exchanger-3 (NHE-3) and Na+/K+ATPase (NKA). Instead of angiotensin II (Ang II), angiotensin III (Ang III) is the predominant endogenous agonist for this response. Exogenous non-peptide AT2R agonist Compound-21 induces natriuresis and lowers blood pressure (BP) in normal and Ang II-infused hypertensive rodents. Spontaneously hypertensive rats (SHR; both pre-hypertensive and hypertensive) have defective natriuretic responses to Ang III, suggesting a defect in AT2R-mediated natriuresis in SHR that leads to hypertension. The mechanisms of deficient AT2R-mediated natriuresis in SHR are unknown but could involve either pre-receptor or receptor/post-receptor defects.

Entities:  

Keywords:  AT2 receptor; Angiotensin receptor; Blood pressure; Hypertension; Natriuresis; Sodium excretion

Mesh:

Substances:

Year:  2017        PMID: 28271418      PMCID: PMC5813476          DOI: 10.1007/s11906-017-0720-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  15 in total

Review 1.  Newly discovered components and actions of the renin-angiotensin system.

Authors:  Robert M Carey
Journal:  Hypertension       Date:  2013-09-30       Impact factor: 10.190

2.  AT2 Receptor Activation Prevents Sodium Retention and Reduces Blood Pressure in Angiotensin II-Dependent Hypertension.

Authors:  Brandon A Kemp; Nancy L Howell; Susanna R Keller; John J Gildea; Shetal H Padia; Robert M Carey
Journal:  Circ Res       Date:  2016-06-20       Impact factor: 17.367

3.  Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats.

Authors:  Shetal H Padia; Brandon A Kemp; Nancy L Howell; Helmy M Siragy; Marie-Claude Fournie-Zaluski; Bernard P Roques; Robert M Carey
Journal:  Hypertension       Date:  2006-12-26       Impact factor: 10.190

4.  Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats.

Authors:  Shetal H Padia; Nancy L Howell; Brandon A Kemp; Marie-Claude Fournie-Zaluski; Bernard P Roques; Robert M Carey
Journal:  Hypertension       Date:  2009-12-07       Impact factor: 10.190

5.  Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.

Authors:  H M Siragy; T Inagami; T Ichiki; R M Carey
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

6.  Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors.

Authors:  Brandon A Kemp; John F Bell; Daniele M Rottkamp; Nancy L Howell; Weijian Shao; L Gabriel Navar; Shetal H Padia; Robert M Carey
Journal:  Hypertension       Date:  2012-06-11       Impact factor: 10.190

7.  AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure.

Authors:  Susan B Gurley; Anne D M Riquier-Brison; Jurgen Schnermann; Matthew A Sparks; Andrew M Allen; Volker H Haase; John N Snouwaert; Thu H Le; Alicia A McDonough; Beverley H Koller; Thomas M Coffman
Journal:  Cell Metab       Date:  2011-04-06       Impact factor: 27.287

8.  Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat.

Authors:  Shetal H Padia; Nancy L Howell; Helmy M Siragy; Robert M Carey
Journal:  Hypertension       Date:  2005-12-27       Impact factor: 10.190

9.  Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney.

Authors:  Steven D Crowley; Susan B Gurley; Maria J Herrera; Phillip Ruiz; Robert Griffiths; Anil P Kumar; Hyung-Suk Kim; Oliver Smithies; Thu H Le; Thomas M Coffman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

10.  Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats.

Authors:  Shetal H Padia; Brandon A Kemp; Nancy L Howell; Marie-Claude Fournie-Zaluski; Bernard P Roques; Robert M Carey
Journal:  Hypertension       Date:  2007-12-24       Impact factor: 10.190

View more
  9 in total

1.  Targeting AT2 receptors in renal disease.

Authors:  Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2021-05-03

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

3.  Endothelial prostaglandin D2 opposes angiotensin II contractions in mouse isolated perfused intracerebral microarterioles.

Authors:  L Li; E Y Lai; X Cao; W J Welch; C S Wilcox
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

4.  Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats.

Authors:  Jay S Mishra; Amar S More; Kathirvel Gopalakrishnan; Sathish Kumar
Journal:  Biol Reprod       Date:  2019-01-01       Impact factor: 4.285

5.  Compromised regulation of the collecting duct ENaC activity in mice lacking AT1a receptor.

Authors:  Mykola Mamenko; Oleg Zaika; Viktor Tomilin; V Behrana Jensen; Oleh Pochynyuk
Journal:  J Cell Physiol       Date:  2018-03-25       Impact factor: 6.384

Review 6.  Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Authors:  Naureen Fatima; Sanket N Patel; Tahir Hussain
Journal:  Hypertension       Date:  2021-04-12       Impact factor: 10.190

7.  Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.

Authors:  Silvana Vasile; Anders Hallberg; Jessica Sallander; Mathias Hallberg; Johan Åqvist; Hugo Gutiérrez-de-Terán
Journal:  Biomolecules       Date:  2020-04-23

8.  A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.

Authors:  Michael R Garvin; Christiane Alvarez; J Izaak Miller; Erica T Prates; Angelica M Walker; B Kirtley Amos; Alan E Mast; Amy Justice; Bruce Aronow; Daniel Jacobson
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.713

Review 9.  Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.

Authors:  Taru Dube; Amrito Ghosh; Jibanananda Mishra; Uday B Kompella; Jiban Jyoti Panda
Journal:  Adv Ther (Weinh)       Date:  2020-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.